Astrazeneca Ab

James Kang

James Woods

Thomas Richard Simpson

Jeffrey Albert

Yan Li

Cristobal Alhambra

Gerard Koether

Ashokkumar Bhikkappa Shenvi

Robert Toms Jacobs

Cyrus Ohnmacht

James Rosamond

Bruce Thomas Dembofsky

Christopher Becker

Gerald M Koether

Gerard M Koether

Jeffrey S Albert

Compounds of Formula I wherein R, A, R, R, R, R, R, n, m, q and r are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

Alkylsulphonamide quinolines

Compounds of Formula I wherein R, A, R, R, R, R, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

Alkyl sulfoxide quinolines as NK-3 receptor ligands

Compounds of Formula II wherein R, A, R, R, R, R, R, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid &#x3b2; protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit &#x3b3; secretase and thereby inhibit the production of amyloid &#x3b2; protein, thereby acting to prevent the formation of neurological deposits of amyloid protein. 

Lactams and uses thereof

Growing community of inventors

Wilmington, DE, United States of America

James Kang